Item 8.01 Other Events.

On January 6, 2022, Hoth Therapeutics, Inc. (the "Company") began dosing to investigate the effect of HT-ALZ on memory, anxiety, and executive function in the APP/PS1+/- mice model after chronic dosing with HT-ALZ.

In addition, on January 6, 2022 (the "Effective Date"), the Company extended the Non-Exclusive Commercial Evaluation License Agreement with Walter Reed Army Institute of Research, a subordinate laboratory of United States Army Medical Research and Materiel Command pursuant to which the term of the agreement was extended for a period of 18 months from the Effective Date.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.   Description
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)




                                       1

© Edgar Online, source Glimpses